Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FND and Bevacizumab for Corneal Neovascularization
NCT07642960Recruiting
- Sponsor
- Ho Chi Minh City Eye Hospital
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Open-label, single-arm trial of bevacizumab in corneal neovascularization (CNV), sponsored by Ho Chi Minh City Eye Hospital. Primary endpoint: Percentage reduction in corneal neovascularization area at 12 months. Started Apr 2026; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
corneal neovascularization (CNV)
Beyond the preview
Go deeper on NCT07642960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07642960.